BLOOD RESEARCH

  • 제53권4호
  • /
  • Pages.281-287
  • /
  • 2018
  • /
  • 2287-979X(pISSN)
  • /
  • 2288-0011(eISSN)
대한혈액학회 (The Korean Society of Hematology)
권호 표지
DOI QR코드

DOI QR Code

Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma

  • Ozpolat, H. Tahsin (Bloodworks Research Institute) ;
  • Yilmaz, Ebru (Department of Nuclear Medicine, Istanbul School of Medicine) ;
  • Goksoy, Hasan Sami (Department of Hematology, Istanbul School of Medicine) ;
  • Ozpolat, Sahre (Department of Biostatistics and Epidemiology, Marmara School of Medicine) ;
  • Dogan, Oner (Department of Pathology, Istanbul School of Medicine) ;
  • Unal, Seher Nilgun (Department of Nuclear Medicine, Istanbul School of Medicine) ;
  • Nalcaci, Meliha (Department of Hematology, Istanbul School of Medicine)
  • 투고 : 2018.02.14
  • 심사 : 2018.05.27
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Background Bone marrow involvement (BMI) affects the lymphoma stage, survival, and treatment. Bone marrow biopsy (BMB) and fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) are useful techniques to detect BMI. Both have advantages and disadvantages. We aimed to identify factors that could be used to predict BMI with positive and negative results on PET/CT compare them with BMB in newly diagnosed patients with lymphoma. Methods We included 22 non-Hodgkin and 16 Hodgkin lymphoma patients in this single center study. All patients had PET/CT examination and BMB before treatment. BMI in BMB was reported as negative or positive. Bone marrow was classified into 3 types by FDG uptake on PT/CT; diffuse involvement, focal involvement, and normal bone marrow. Results PET/CT and BMB results were concordant (7 positive, 15 negative) in 22 patients (57%). We evaluated concordant and discordant patient characteristics and risk-stratified patients for BMI. Our findings suggest that patients with diffuse FDG uptake on PET/CT, especially patients with advanced age and low platelet and white blood cell counts, are likely to have BMI and could potentially forego BMB. Patients with negative PET/CT findings and no significant laboratory abnormalities are very unlikely to have BMI. Conclusion Our results suggest that BMI should not be decided solely based PET/CT or BMB findings. It is reasonable to use both diagnostic assays along with clinical and laboratory findings. PET/CT result, clinical and laboratory findings could be useful for predicting BMI in patient for whom BMB is contraindicated.

키워드

참고문헌

  1. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81. https://doi.org/10.1148/radiology.206.2.9457202
  2. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356-67.
  3. El Karak F, Bou-Orm IR, Ghosn M, et al. PET/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma. PLoS One 2017;12:e0170299. https://doi.org/10.1371/journal.pone.0170299
  4. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. https://doi.org/10.1182/blood-2003-12-4434
  5. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14. https://doi.org/10.1056/NEJM199811193392104
  6. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-62. https://doi.org/10.1200/JCO.2008.21.3991
  7. National Cancer Institute. Survival. Bethesda, MD: National Cancer Institute, 2018. (Accessed October 2, 2018, at https://progressreport.cancer.gov/after/survival).
  8. Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009;36(4 Suppl 2):S2-16. https://doi.org/10.1053/j.seminoncol.2009.05.002
  9. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol 2009;11:269-74. https://doi.org/10.1007/s11307-009-0200-9
  10. Fuertes S, Setoain X, Lopez-Guillermo A, et al. The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma. Med Clin (Barc) 2007;129:688-93. https://doi.org/10.1157/13112510
  11. Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325-9. https://doi.org/10.1007/s00259-003-1375-y
  12. McKenna RW, Bloomfield CD, Brunning RD. Nodular lymphoma: bone marrow and blood manifestations. Cancer 1975;36:428-40. https://doi.org/10.1002/1097-0142(197508)36:2<428::AID-CNCR2820360218>3.0.CO;2-H
  13. Mckenna RW. The bone marrow manifestations of Hodgkin's disease, the non-Hodgkin's lymphomas and lymphoma-like disorders. In: Dunphy CH. Neoplastic hematopathology. 1st ed. Baltimore, MD: Williams & Wilkins, 1992:1156.
  14. Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma 2004;5:62-4. https://doi.org/10.3816/CLM.2004.n.012
  15. Aflalo-Hazan V, Gutman F, Kerrou K, Montravers F, Grahek D, Talbot JN. Increased FDG uptake by bone marrow in major beta-thalassemia. Clin Nucl Med 2005;30:754-5. https://doi.org/10.1097/01.rlu.0000183610.66162.29
  16. Murata Y, Kubota K, Yukihiro M, Ito K, Watanabe H, Shibuya H. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol 2006;33:999-1004. https://doi.org/10.1016/j.nucmedbio.2006.09.005
  17. El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatmentnaive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508-14. https://doi.org/10.1200/JCO.2012.42.4036
  18. Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. Eur J Haematol 2015;95:83-9. https://doi.org/10.1111/ejh.12483
  19. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958-63.
  20. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889-99. https://doi.org/10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5
  21. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6. https://doi.org/10.1182/blood.V91.9.3340
  22. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S113-20. https://doi.org/10.1007/s00259-008-0951-6
  23. Heacock L, Weissbrot J, Raad R, et al. PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 2015;204:842-8. https://doi.org/10.2214/AJR.14.13181

피인용 문헌

  1. Ewing Sarcoma Family Tumors: Past, Present and Future Prospects vol.16, pp.None, 2018, https://doi.org/10.2174/1573394716999201125204643
  2. Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-03278-9
  3. FDG PET/CT versus Bone Marrow Biopsy for Diagnosis of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Systematic Review vol.12, pp.2, 2018, https://doi.org/10.3390/app12020540